1. Home
  2. DRCT vs INAB Comparison

DRCT vs INAB Comparison

Compare DRCT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$0.10

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.79

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRCT
INAB
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
10.6M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
DRCT
INAB
Price
$0.10
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$108.00
AVG Volume (30 Days)
27.8M
59.0K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,369,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$25.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$1.53
52 Week High
$6.59
$12.53

Technical Indicators

Market Signals
Indicator
DRCT
INAB
Relative Strength Index (RSI) 24.96 49.97
Support Level $0.09 $1.73
Resistance Level $0.18 $2.11
Average True Range (ATR) 0.03 0.14
MACD -0.00 0.03
Stochastic Oscillator 8.15 51.07

Price Performance

Historical Comparison
DRCT
INAB

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: